Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways.

Vicari D, Foy KC, Liotta EM, Kaumaya PT.

J Biol Chem. 2011 Apr 15;286(15):13612-25. doi: 10.1074/jbc.M110.216812. Epub 2011 Feb 14.

2.
3.

The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.

Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, Wedge SR, Jürgensmeier JM, Alitalo K.

Cancer Res. 2008 Jun 15;68(12):4754-62. doi: 10.1158/0008-5472.CAN-07-5809.

4.

A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo.

Rastelli L, Valentino ML, Minderman MC, Landin J, Malyankar UM, Lescoe MK, Kitson R, Brunson K, Souan L, Forenza S, Goldfarb RH, Rabbani SA.

Int J Oncol. 2011 Aug;39(2):401-8. doi: 10.3892/ijo.2011.1040. Epub 2011 May 11.

PMID:
21567086
5.

Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.

Huang SW, Lien JC, Kuo SC, Huang TF.

Carcinogenesis. 2012 May;33(5):1022-30. doi: 10.1093/carcin/bgs127. Epub 2012 Mar 20.

PMID:
22436611
6.

Characterization of a designed vascular endothelial growth factor receptor antagonist helical peptide with antiangiogenic activity in vivo.

Basile A, Del Gatto A, Diana D, Di Stasi R, Falco A, Festa M, Rosati A, Barbieri A, Franco R, Arra C, Pedone C, Fattorusso R, Turco MC, D'Andrea LD.

J Med Chem. 2011 Mar 10;54(5):1391-400. doi: 10.1021/jm101435r. Epub 2011 Jan 31.

PMID:
21280635
7.

Alzheimer's beta-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2.

Patel NS, Mathura VS, Bachmeier C, Beaulieu-Abdelahad D, Laporte V, Weeks O, Mullan M, Paris D.

J Neurochem. 2010 Jan;112(1):66-76. doi: 10.1111/j.1471-4159.2009.06426.x. Epub 2009 Oct 10.

8.

Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo.

Foy KC, Liu Z, Phillips G, Miller M, Kaumaya PT.

J Biol Chem. 2011 Apr 15;286(15):13626-37. doi: 10.1074/jbc.M110.216820. Epub 2011 Feb 16.

9.

Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling.

Awasthi N, Schwarz MA, Verma V, Cappiello C, Schwarz RE.

Lab Invest. 2009 Jan;89(1):38-46. doi: 10.1038/labinvest.2008.106. Epub 2008 Nov 10.

10.
11.

Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer.

Wang N, Wang ZY, Mo SL, Loo TY, Wang DM, Luo HB, Yang DP, Chen YL, Shen JG, Chen JP.

Breast Cancer Res Treat. 2012 Aug;134(3):943-55. doi: 10.1007/s10549-012-1977-9. Epub 2012 Feb 21.

12.

Rational design, structure, and biological evaluation of cyclic peptides mimicking the vascular endothelial growth factor.

Goncalves V, Gautier B, Coric P, Bouaziz S, Lenoir C, Garbay C, Vidal M, Inguimbert N.

J Med Chem. 2007 Oct 18;50(21):5135-46. Epub 2007 Sep 27.

PMID:
17900101
13.

A serum-stable branched dimeric anti-VEGF peptide blocks tumor growth via anti-angiogenic activity.

Kim JW, Kim TD, Hong BS, Kim OY, Yoon WH, Chae CB, Gho YS.

Exp Mol Med. 2010 Jul 31;42(7):514-23.

14.

A fusion protein with the receptor-binding domain of vascular endothelial growth factor-A (VEGF-A) is an antagonist of angiogenesis in cancer treatment: Simultaneous blocking of VEGF receptor-1 and 2.

Tseng FJ, Chen YC, Lin YL, Tsai NM, Lee RP, Chung YS, Chen CH, Liu YK, Huang YS, Hwang CH, Lai YK, Liao KW.

Cancer Biol Ther. 2010 Nov 1;10(9):865-73. doi: 10.4161/cbt.10.9.13230. Epub 2010 Nov 1.

PMID:
20818186
15.

A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.

LaMontagne KR, Butler J, Borowski VB, Fuentes-Pesquera AR, Blevitt JM, Huang S, Li R, Connolly PJ, Greenberger LM.

Angiogenesis. 2009;12(3):287-96. doi: 10.1007/s10456-009-9151-7. Epub 2009 Jun 21.

PMID:
19544081
16.

UPARANT: a urokinase receptor-derived peptide inhibitor of VEGF-driven angiogenesis with enhanced stability and in vitro and in vivo potency.

Carriero MV, Bifulco K, Minopoli M, Lista L, Maglio O, Mele L, Di Carluccio G, De Rosa M, Pavone V.

Mol Cancer Ther. 2014 May;13(5):1092-104. doi: 10.1158/1535-7163.MCT-13-0949. Epub 2014 Apr 4.

17.

Development of a highly-potent anti-angiogenic VEGF8-109 heterodimer by directed blocking of its VEGFR-2 binding site.

Ghavamipour F, Shahangian SS, Sajedi RH, Arab SS, Mansouri K, Aghamaali MR.

FEBS J. 2014 Oct;281(19):4479-94. doi: 10.1111/febs.12956. Epub 2014 Sep 1.

18.

Tissue inhibitor of metalloproteinases-3 peptides inhibit angiogenesis and choroidal neovascularization in mice.

Qi JH, Ebrahem Q, Ali M, Cutler A, Bell B, Prayson N, Sears J, Knauper V, Murphy G, Anand-Apte B.

PLoS One. 2013;8(3):e55667. doi: 10.1371/journal.pone.0055667. Epub 2013 Mar 1.

19.

Anti-angiogenic activity of carebastine: a plausible mechanism affecting airway remodelling.

De Luisi A, Mangialardi G, Ria R, Acuto G, Ribatti D, Vacca A.

Eur Respir J. 2009 Oct;34(4):958-66. doi: 10.1183/09031936.00165308. Epub 2009 Apr 8.

20.

Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.

Chung TW, Kim SJ, Choi HJ, Kim KJ, Kim MJ, Kim SH, Lee HJ, Ko JH, Lee YC, Suzuki A, Kim CH.

Glycobiology. 2009 Mar;19(3):229-39. doi: 10.1093/glycob/cwn114. Epub 2008 Oct 30.

PMID:
18974200

Supplemental Content

Support Center